CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer

Official title

Safety and Feasibility of CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer (PANCOSIL): an Open-label, Single-arm Phase 1-2 Feasibility Study

Overview

Pancreatic ductal adenocarcinoma is a highly lethal cancer, and approximately 40% of patients present with non-metastatic locally advanced pancreatic cancer (LAPC) that is not suitable for surgical resection. To improve outcomes in this patient group, local ablative treatments are being explored. Radionuclide therapy (RNT) is a promising option that delivers high-dose internal radiation directly into the tumor, potentially achieving better local tumor control while sparing surrounding tissues compared with external-beam radiation therapy. The OncoSil™ device is a type of RNT containing Phosphorus-32-radiolabeled microparticles. The ³²P microparticles have been designed to deliver a localized distribution of beta-radiation within the target tumor up to 100 Gy, which causes direct damage to cancer cell DNA and renders them incapable of further cell division and proliferation. Favorable results have been reported by implanting ³²P microparticles intra-tumorally, which is typically administered via endoscopic ultrasound guidance. A percutaneous approach may allow for more precise and reproducible delivery, but prospective data on its safety and feasibility are lacking. This prospective, single-arm phase 1-2 feasibility study aims to evaluate the safety and feasibility of percutaneous CT- guided RNT using ³²P microparticles in patients with non-progressive LAPC following induction chemotherapy. Twenty adult patients with pathology-confirmed LAPC, showing non-progressive disease according to RECIST, will be included after multidisciplinary tumor board review. Patients will undergo percutaneous, CT-guided implantation of ³²P microparticles under general anesthesia, sedation, or local analgesia depending on study phase and clinical judgment, followed by continuation of standard systemic chemotherapy and routine follow-up. The primary endpoint is the rate of adverse events (CTCAE grade ≥3) occurring during the procedure and within 90 days afterward. Secondary endpoints include technical success, all adverse events, best overall respons, overall and progression-free survival, and changes in tumor markers.

Interventions

• Device CT-guided percutaneous intratumoural implantation of the OncoSil™ device
  CT-guided percutaneous intratumoural implantation of the OncoSil™ device, containing ³²P microparticles as a form of radionucleide therapy for 20 patients diagnosed with RECIST-stable LAPC after 2 months of systemic therapy.

Primary outcome measures

• Safety defined as the rate of procedure- or device-related CTCAE grade ≥3 adverse events (AEs) within 90 days after implantion. [Time frame: From implantation to 90 days after implantation]

Secondary outcome measures (8)

• Technical succes defined a the rate of adequate punctures and subsequent complete intratumoral delivery of the planned dose. [Time frame: Periprocedural.]
• Overall safety defined as the rate of adverse events. [Time frame: From implantation until 90 days after implantation.]
• Duration of implantation procedure defined as the total time of punction. [Time frame: Periprocedural.]
• Duration of overall procedure defined as the total time in the radiology suite. [Time frame: Periprocedural.]
• Overall survival [Time frame: Defined from diagnosis and from implantion untill death by any cause, assessed up to end of study or up to 1 year after implantation.]
• Local, distant and overall progression free survival [Time frame: Defined from diagnosis and from implantation until local and/or distant progression, or death, assessed up to end of study or up to 1 year after implantation.]
• Changes in serum CA19.9 during the first three months after implantation. [Time frame: From implantation until three months after implantation.]
• Visual confirmation of intra-tumoral delivery of ³²P microparticles or other off-target deposition. [Time frame: SPECT-imaging at +4 hours and +7 days after implantation.]

Eligibility criteria

Inclusion criteria

• Age ≥18 years
• Locally advanced pancreatic cancer, defined by the DPCG consensus criteria as: arterial involvement >90 degrees or venous involvement >270 degrees.
• At least RECIST stable disease after a minimum two months of chemotherapy according to current clinical practice\*
• Capable of providing written and oral informed consent
• Candidate for RNT, judged by a multidisciplinary tumor board
• WHO 0-2

Exclusion criteria

• Eligibility for resection
• Participation in other trials focussing on different ablative treatment modalities such as radiofrequency ablation or irreversible electroporation for LAPC
• Known hypersensitivity to silicon or phosphor
• Bleeding disorders which cannot be corrected with medication
• Inability/unwillingness to interrupt anticoagulation therapy
• Pregnancy
• Metastatic pancreatic cancer
• Epilepsy episode(s) in the past six months
• Longest tumor diameter >70 mm or total target tumor volume >110 ml
• Presence of multiple collateral vessels surrounding or adjacent to the target tumor on radiologic imagining, prohibiting safe injection of the OncosilTM device
• Presence (or significant risk) of varices near the target tumor on radiologic imaging
• Recent clinically significant pancreatitis
• Previous administration of radiotherapy to the pancreas

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Netherlands · 1 center

• Amsterdam UMC - Location VUmc — Amsterdam

Identifiers

NCT: NCT07595835 · NL78596.000.22

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗